Cybin FDA Milestone Amidst Financial Burn-rate
The TDR Three Takeaways: 1. FDA Approval for Phase 2a Study: Cybin has received FDA clearance to begin a Phase 2a study of CYB004, a
The TDR Three Takeaways: 1. FDA Approval for Phase 2a Study: Cybin has received FDA clearance to begin a Phase 2a study of CYB004, a
The TDR Three Key Takeaways: 1. Severe Financial Strain: Seelos Therapeutics is facing significant financial difficulties, evident from a 117% dilution of equity investors and
Steward Health Care, a for-profit health system that serves thousands of patients in Eastern Massachusetts, is in such grave financial distress that it may be
IntelliGenes, a first of its kind software created at Rutgers Health, combines artificial intelligence (AI) and machine-learning approaches to measure the significance of specific genomic
A new study at the University of Missouri’s Thompson Center for Autism and Neurodevelopment found that propranolol, a medication that treats high blood pressure, can
Ozempic and other GLP1 agonists are associated with a reduced risk of developing cirrhosis and liver cancer in people with type 2 diabetes and chronic
A research team led by Georg Stary (Medical University of Vienna and CeMM) has identified a new approach to treating the inflammatory disease sarcoidosis.
Researchers from two Lithuanian universities have developed a patient-safe monitoring technology to identify and manage individual factors provoking atrial fibrillation.
A combination therapy with multiple drugs is more effective than just one active compound. To begin with, at least.